
LSTA Stock Forecast & Price Target
LSTA Analyst Ratings
Bulls say
Lisata Therapeutics Inc has shown significant progress in the development of its lead investigational drug, certepetide, which aims to enhance the efficacy of anti-cancer therapies for solid tumors. Preliminary data from Cohort A and further insights from Cohort B indicate a promising trend in overall survival, with a notable number of complete responses, suggesting its potential to improve progression-free survival (PFS) and overall response rate (ORR) for patients suffering from metastatic pancreatic ductal adenocarcinoma (mPDAC). The advancements in clinical data reinforce the potential value of certepetide in treating complex conditions, contributing to a positive financial outlook for the company.
Bears say
Lisata Therapeutics Inc's stock outlook is negatively influenced by several fundamental factors, primarily including the potential for failed or inconclusive clinical trials, which could significantly hinder the development of its investigational product, certepetide. Additionally, the company's ability to secure adequate funding remains critical, as insufficient financial resources could stall or prevent the progress of its drug development efforts. The combination of these risks poses considerable uncertainty regarding the future valuation and prospects for reaching key financial targets.
This aggregate rating is based on analysts' research of Lisata Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LSTA Analyst Forecast & Price Prediction
Start investing in LSTA
Order type
Buy in
Order amount
Est. shares
0 shares